New Mesothelioma Test Available Later This Year
A mesothelioma test created and validated at Brigham and Women/s Hospital in Boston could be available to the public within the next couple of months. The test, which will be known by the brand name DecisionDx-Mesothelioma, is designed to test patients who are suspected of having mesothelioma for the expression of a variety of genes. By creating a gene profile, the test can give doctors a clearer picture of which patients with mesothelioma symptoms might actually be suffering from the disease. Friendswood, Texas-based Castle Biosciences has announced that it has acquired the intellectual property and technology rights to the test from Brigham and Women’s. Castle Biosciences specializes in molecular diagnostic tests for rare cancers like mesothelioma. Currently, the company has three proprietary…